Tavistock GIDS: rise, whistleblowers and closure

How did the Gender Identity Development Service grow, who raised the alarm, and why was it closed?

The Gender Identity Development Service (GIDS), run by the Tavistock and Portman NHS Foundation Trust, was for many years England’s sole national specialist service for children and young people experiencing gender-related distress. Its centralised structure meant that referrals from across England, and at points from other UK nations, were channelled towards one provider and associated satellite clinics.

Background

The Gender Identity Development Service (GIDS), run by the Tavistock and Portman NHS Foundation Trust, was for many years England’s sole national specialist service for children and young people experiencing gender-related distress. Its centralised structure meant that referrals from across England, and at points from other UK nations, were channelled towards one provider and associated satellite clinics.

The scale and character of demand changed markedly. The Employment Tribunal judgment in Appleby v Tavistock and Portman NHS Foundation Trust records 1,408 referrals in 2016–17 and 2,728 in 2019–20, following sustained annual growth from 2009. It also records a major change in the referred population: whereas boys had initially predominated, 76% of referrals in 2019 were of young people recorded as female at birth (Employment Tribunal, 2021). NHS England’s terms of reference for the Cass Review acknowledged both the sharp rise in referrals and the service’s movement from a psychosocial and psychotherapeutic model to one which also involved referral for hormone treatment (NHS England, 2020).

GIDS did not itself prescribe puberty blockers or masculinising and feminising hormones. It assessed patients and could refer them to specialist paediatric endocrine teams, principally at University College London Hospitals and Leeds Teaching Hospitals. That distinction matters, but it does not remove GIDS from the clinical pathway: assessment, diagnostic formulation, safeguarding, information-sharing and referral were central functions of the service.

Demand outstripped capacity. The Care Quality Commission’s 2021 inspection found a waiting list exceeding 4,600 young people, with some waiting more than two years for a first appointment. It found that many waiting patients were vulnerable or at risk of self-harm, while GIDS lacked the capacity to manage risks proactively for those awaiting assessment (CQC, 2021).

What the documents say

Warnings from within the service

Concerns did not originate with one campaign, court case or report. They arose over years from clinicians, safeguarding staff, regulators, patients and families. The most important documentary record is the Employment Tribunal judgment concerning Sonia Appleby, the Trust’s safeguarding lead. The Tribunal found that the Trust subjected Appleby to detriment because of protected whistleblowing disclosures and awarded her £20,000 for injury to feelings (Employment Tribunal, 2021).

The judgment records that GIDS staff raised concerns with Appleby from October 2017. These included a culture in which some staff felt unable to raise safeguarding issues for fear of being labelled “transphobic”, uncertainty about clinical management, high caseloads and questions about patients’ capacity to consent. In early 2018, ten concerned GIDS staff also approached Dr David Bell, then the staff representative on the Trust’s Council of Governors. Bell subsequently produced his report, Serious Concerns Regarding the Gender Identity Service, in 2018.

Appleby did not endorse every aspect or the tone of Bell’s report. The Tribunal explicitly notes that she agreed safeguarding was not being handled properly but did not agree with all his framing. This distinction is important. The legal finding was not that every allegation made by Bell was proved. It was that Appleby’s public-interest safeguarding disclosures were protected and that she suffered detriment because she made them.

Regulatory and patient-safety findings

The CQC’s focused inspection, published in January 2021, identified shortcomings in waiting-list management, risk management, record-keeping and staff experience. The later Healthcare Safety Investigation Branch report summarised the regulator’s findings: staff did not always feel respected, supported or valued, and some said they feared repercussions if they raised concerns. It also identified the absence of proactive risk management for many vulnerable children waiting for a first appointment (HSSIB, 2022).

The Cass Review was commissioned by NHS England in September 2020. Its terms of reference required examination of the reasons for the rise in referrals, especially the disproportionate increase among girls; clinical pathways; hormone interventions; audit; long-term follow-up; and the needs of children with complex presentations (NHS England, 2020). Cass’s interim report in 2022 concluded that the single-provider model could not safely or sustainably meet demand and recommended regional services led by specialist children’s hospitals.

The final report, published on 10 April 2024, found that the evidence base for puberty suppression and masculinising or feminising hormones in adolescents was weak, with significant uncertainty about longer-term outcomes. It called for careful, holistic assessment of mental health, neurodevelopmental conditions, family circumstances, sexuality and other factors that may be relevant to a young person’s distress (Cass Review, 2024).

The courts

The litigation in Bell v Tavistock concerned consent to puberty blockers, not the whole future of GIDS. In December 2020, the High Court issued a declaration indicating that it was highly unlikely that a child aged 13 or under could be competent to consent to puberty blockers, and doubtful that many aged 14 or 15 could understand and weigh the relevant information. The Court of Appeal overturned that declaration on 17 September 2021. It held that the question of Gillick competence was for clinicians to decide in individual cases under ordinary legal principles, and that the claim should have been dismissed. The Supreme Court refused permission to appeal on 28 April 2022.

The legal outcome therefore did not close GIDS and did not establish that its clinicians had acted unlawfully. It did, however, place consent, uncertainty, fertility and the relationship between puberty blockers and later treatment at the centre of public scrutiny. The subsequent closure was an NHS England commissioning decision following the Cass Review’s interim advice, not a court order.

The positions

Supporters of the former GIDS model argued that gender-distressed children needed a dedicated national service and that long waits, rather than the existence of specialist care, were the principal danger. They have also argued that restrictions on medical treatment risk leaving distressed young people without support, and that the hostile public debate can itself damage wellbeing.

Critics, including former staff, some parents and gender-critical campaigners, argued that the service had become overly affirming, insufficiently curious about co-existing difficulties and too ready to place distressed adolescents on a medical pathway despite uncertain evidence. They point to the whistleblowing evidence, CQC findings, the lack of systematic long-term outcome data and the sharp demographic change among referrals.

NHS England’s position is neither that all young people should be denied specialist help nor that the former model should continue. Its replacement service specification adopts a more cautious, multidisciplinary approach, with greater involvement of paediatrics and children’s mental-health services, psychosocial support and regional clinical networks. Puberty blockers are no longer routinely commissioned by NHS England for under-18s with gender incongruence or gender dysphoria.

Interpretation

Beyond Gender’s reading is that GIDS failed because an exceptional rise in demand met a single, poorly governed national service that had moved towards medical intervention without the evidence, data systems, independent challenge or safeguarding architecture required for such a high-stakes pathway. The closure should not be understood as a verdict on every clinician or every patient’s experience. Many staff worked conscientiously, and some families reported positive care.

But institutional failure is often visible precisely when individual professionals attempt to compensate for an unsafe system. The warnings from Appleby, Bell and other staff, the CQC’s findings, the excessive waits and Cass’s conclusions form a cumulative record. That record suggests that children with varied and sometimes complex causes of distress were too often processed through a service configured around gender identity rather than given adequately broad, evidence-led assessment first.

The central lesson is not that children should receive no help. It is that help must not require a child to adopt a particular identity, nor treat social or medical transition as the default answer to distress. The NHS should retain an insistence on safeguarding, developmental caution, meaningful parental involvement, high-quality data and genuine alternatives.

Open questions

Long-term outcomes remain the largest unresolved issue. The Cass Review called for robust follow-up of former GIDS patients, including those who proceeded with medical treatment, those who did not, and those whose identity or treatment goals changed. Without this work, the NHS cannot properly evaluate benefits, harms, discontinuation, regret, fertility outcomes, sexual development or mental-health trajectories.

There are also accountability questions. What action did the Trust take in response to repeated staff concerns before external scrutiny intensified? How were safeguarding concerns recorded, escalated and audited? Why was the service allowed to retain a national monopoly while demand and waiting times rose so dramatically? These questions concern governance, not merely ideology.

Finally, the replacement regional model must be judged by outcomes rather than assurances. It should be transparent about referrals, assessments, co-existing conditions, treatment decisions, waiting times and follow-up. Parents, clinicians, journalists and Parliament should expect routine publication of that evidence.

On the UK timeline

Episodes on this subject

"The Biggest Scandal Since Lobotomies" - Tavistock Whistleblower Marcus Evans

Gender Clinic Whistleblower Thought She Was Helping Kids but She Was Wrong | Jamie Reed (#49)

The Truth Gender Clinicians Tried to Ignore - Dr Susan Bradley (#43)